Biotech Analysts, along with expert pulmonologist Dr. Tisha Wang, discuss the opportunity and expectations for Savara’s (SVRA) molgramostim which addresses the root cause of autoimmune Pulmonary Alveolar Proteinosis (aPAP) on an Analyst/Industry conference call to be held on April 30 at 1 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA: